Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 1294 漢田生技. Please read: https://finlab.finance/en/setup?stock=1294

No install, open FinLab Studio

1294

漢田生技 Food As of 2026-06-17 Updated daily after market close

strong quality, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 漢田生技 to your watchlist to track signal changes on your next visit.
Valuation 64Quality 86Growth 74Momentum 44Chips 12

Is 漢田生技 a buy? Fundamentals and valuation first

  • Top-tier profitability.Operating margin beats ~87% of the market. Latest quarterly ROE ≈ 5.0%.

  • Valuation is neutral.PE is in the 32th market percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -4.3% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 31.2%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.34
BearishNeutralBullish

Institutional rotation, concentration steady — bullish

  • Institutional rotation, concentration steady — bullish
  • 富邦-南員林 holds 234 lots
  • sellers have 21 lots left, ~28 sessions to clear

Window from 2026-01-17 · Price +2% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 富邦-南員林 has accumulated 234 lots since the start (sold 0%), holding.
  • Main distributor 群益金鼎-東門 peaked at 80 lots, has sold 85%, 12 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders +0, retail +0.10pp — little change.
  • Foreign hedge-desk net short Net short -87 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
富邦-南員林亞東群益金鼎-北高雄國泰-敦南永豐金-員林元大-東泰
Distributing
群益金鼎-東門美林元大-古亭元大-員林統一-彰化富邦-建國
Desks
own scale
光和-溪湖合庫-彰化元大-六合富邦-員林
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 富邦-南員林 +234
    sold 0%
  • 亞東 +119
    sold 0%· still adding
  • 群益金鼎-北高雄 +38
    sold 3%· still adding
  • 國泰-敦南 +37
    sold 0%· still adding
  • 永豐金-員林 +33
    sold 8%
  • 元大-東泰 +29
    sold 0%

Distributing

  • 群益金鼎-東門 12 left
    sold 85%· paused recently
  • 美林 34 left
    sold 28%· paused recently
  • 元大-古亭 4 left
    sold 86%· paused recently
  • 元大-員林 19 left
    sold 32%· paused recently
  • 統一-彰化 14 left
    sold 46%· ~28 sessions to clear
  • 富邦-建國 16 left
    sold 27%· paused recently

Desks

  • 光和-溪湖 -248
    unclassified
  • 合庫-彰化 -82
    unclassified
  • 元大-六合 -74
    unclassified
  • 富邦-員林 -67
    unclassified
Still selling 21 lots ~28 sessions to bottom at most
Recent buy/sell force +200 absorbed / -14 sold buyers slightly ahead
Hedge-desk net short -1 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 31.23%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

6 historical occurrences (since 2025-10-13)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 60%, Sample 5, Median +2.61%, Excess -2.46%, Beat mkt rate 60%；60-day: Win 60%, Sample 5, Median +6.33%, Excess -15.19%, Beat mkt rate 0%

60 days after: historical avg +3.38%

20-day +1.38%
60-day +3.38%
20-day
60-day
Win
60%
60%
Sample
5
5
Median
+2.61%
+6.33%
Excess
-2.46%
-15.19%
Beat mkt rate
60%
0%

Over 5 occurrences, 60-day forward avg gained 3.38%, lagged the market by 15.19 pts; win rate 60%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

What does 漢田生技 do? Company profile

食品工業／食品生技／保健食品 ODM/OEM 櫃買中心上櫃

Overview

漢田生技股份有限公司，統一編號28814153，成立於2007/10/22，股票代號1294，為櫃買中心上櫃普通股，2024/09/26掛牌上櫃。公司地址為彰化縣溪湖鎮西溪里工業路101號；公開資料另有早期總部位於彰化縣員林市之描述，現行公司網站與股市基本資料以溪湖地址為準。董事長李雨霖；總經理王國華；發言人王國華；代理發言人謝駿陽。實收資本額約新台幣3.05至3.06億元，已發行股數約3,057.16萬股。主要業務為機能性飲品ODM/OEM、粉體原料及膠囊。2026/05單月合併營收6,828.6萬元、年增31.23%，2026年前五月累計營收3.7299億元、年增24.73%。2025全年營收約7.78543億元、年增4.02%；新聞來源揭露2025營業利益約1.73億元、歸母淨利約1.39億元、EPS約4.60元。2024全年合併營收7.48423億元、歸母淨利1.55674億元、EPS 6.02元。員工規模：本次可直接擷取來源未取得最新正式員工人數；Goodinfo揭露2025全體員工平均年薪75.1萬元。主要股東：鉅亨網揭露董事李雨霖持股約77.157萬股、尚文約60.2154萬股，但完整前十大持股明細需以公開資訊觀測站最新股東會年報為準；另舊資料顯示111/04/30前十大包含漢碩投資、漢畿投資、曾士哲、李雨霖等，因年代較舊僅作歷史參考。子公司／關係企業方面，MoneyDJ資料指出2021年成立百維生技股份有限公司，負責進口經銷全球保健食品原料、整合上下游資源；EMIS資料另列漢基科技股份有限公司持股80.4%，但細節需以年報確認。

Business

漢田生技定位為台灣領導液劑、果凍、晶凍類保健食品代工廠，採ODM/OEM與顧問式一站式服務模式，服務範圍涵蓋概念提案、劑型選擇、獨特原料、產品研發、袋型選定、軟袋設計、外盒設計與後端輔銷。主要產品包含各類機能性保健飲品、晶凍、直飲液、濃縮漿、碎凍、粉包、膠囊、錠劑、珍珠粉與龜鹿二仙膠等。產品包材與劑型主打軟袋／鋁箔袋，可支援方形袋、曲線瓶、圓口瓶、Z型袋、酒瓶袋、小立袋、大立袋等造型，容量約10至80ml(g)。2024年產品結構多個資料源顯示機能性飲品約95%、粉體原料及膠囊約4%至4.7%、其他約0.5%；區域銷售以台灣內銷為主，MoneyDJ揭露2024內銷約98%、外銷約2%，另一來源細分台灣98.59%、中國1.30%、其他0.11%。主要客戶群為國內外保健食品品牌、藥廠、生技生醫公司、原料商、電商／直播通路、藥局藥妝、直銷與超市等；MoneyDJ指出機能性飲品最大客戶為軒郁。商業模式核心在於協助品牌商快速推出液態與晶凍型保健食品，透過配方開發、原料整合、殺菌軟袋充填包裝、品管認證與量產能力取得代工訂單。公司網站宣稱全台灣最大鋁箔包飲品產能，與主要競爭對手約4倍以上產能差距；2026年新聞提及具1.91億包年產能、每年可推出超過170項新品、客戶留存率長期約80%以上，但此等營運指標需以公司法說或年報再驗證。公司通過ISO22000、HACCP、食品業者衛生安全二級品管、保健食品GMP、HALAL清真等認證。

Outlook 2025–2028

2025年已結束，全年營收約7.785億元、年增約4%，雖然前三季受部分客戶庫存調節影響，但2025年9月至12月營收年增率連續高於三成，12月單月營收8,364萬元創高，顯示品牌端拉貨回溫。2026年前五月累計營收3.73億元、年增24.73%，累計營收連續五個月改寫同期新高；公司與新聞來源均指向2026全年以雙位數成長為目標，主要動能包含既有客戶回補訂單、新品推出、節慶檔期備貨、素材升級、通路拓展與海外布局。公司已與某上櫃功能性益生菌原料商合作開發液態益生菌產品，若量產順利，有助於提高高附加價值品項占比。通路端除原有電商／品牌客戶外，將加速藥局、直銷、超市等過去滲透率較低通路；海外端看東南亞需求增強，並與國際直銷品牌洽談，2026至2027年可能逐步規模化貢獻。產業面，2024年台灣保健飲品占整體保健食品市場約11.3%、市場規模約203.5億元；新聞引述Grand View預估台灣保健飲品未來五年CAGR約10.6%。軟袋在液態保健飲品滲透率估約3.7%，公司與新聞來源預估未來五年台灣軟袋保健飲品市場仍有15%至20%年成長空間，液態、晶凍劑型取代膠囊、錠劑與傳統包材是中期趨勢。2027至2028年展望屬推估：若公司可維持產能利用率提升、製程效率改善、海外與新通路放量，營運槓桿可改善固定成本吸收並提升獲利彈性；公司稱現有產能充足，未來3至5年可在不需大型資本支出的前提下以稼動率提升放大獲利。主要風險包括主要客戶訂單波動與庫存調節、銷售集中度、原料與包材成本波動、食品安全與法規認證、軟袋包材滲透不如預期、海外市場開發時程不確定、同業擴產競爭，以及高配息與成長投資之間的資本配置壓力。

Supply Chain

Upstream
  • 百維生技股份有限公司 漢田生技轉投資公司，MoneyDJ資料稱其進口經銷全球保健食品原料，整合上下游資源並降低採購成本；未上市櫃。
  • 未揭露之上櫃功能性益生菌原料商 MoneyDJ新聞稱漢田已與某上櫃功能性益生菌原料商合作開發液態益生菌產品，但報導未揭露公司名稱，故stock_id設為null。
  • 包材、濃縮果汁、珍珠粒、鹿角、植物萃取物等供應商 MoneyDJ資料列為主要原物料來源，包含軟袋／鋁箔袋包材、食品原料與漢方素材；具體供應商未揭露。
  • 國際原料生產廠商 透過百維生技與國際原料開發單位直接接洽並進口保健食品原料；多為海外或未揭露供應商。
Downstream
  • 軒郁國際 6703 MoneyDJ資料指出軒郁為漢田機能性飲品最大客戶；軒郁為台股上櫃公司，主要經營美妝保健品牌與通路。
  • 國內外保健食品品牌商 漢田主要ODM/OEM客戶群，委託其開發與生產液態、晶凍、粉包、膠囊等保健食品；多數個別公司名稱未揭露。
  • 藥廠、生技生醫公司與原料商 MoneyDJ資料列為主要銷售及代工對象，涉及保健食品產品化與通路銷售；具體公司未揭露。
  • 電商／直播、藥局藥妝、直銷、超市等通路客戶 2026年展望資料指出公司將擴大切入藥局、直銷、超市並延續電商通路；多為品牌商或通路商，未能逐一確認台股代號。
  • 東南亞客戶與國際直銷品牌 MoneyDJ新聞指出東南亞需求增強、並與國際直銷品牌洽談，2026至2027年有機會逐步規模化貢獻；具體公司未揭露。

Competitors

  • 葡萄王 1707 台股上市公司，保健食品、益生菌、發酵與生技食品相關業務；MoneyDJ列為漢田競爭對手。
  • 大江生醫 8436 台股上櫃公司，保健食品與生技ODM/CDMO大廠；MoneyDJ列為競爭對手。
  • 金穎生技 1796 台股上櫃公司，益生菌與機能素材相關業務；MoneyDJ列為競爭對手。
  • 生合生物科技 1295 台股上櫃公司，益生菌原料與保健食品相關業務；StockFeel列為同業競爭者。
  • 晨暉生技 台股興櫃／上櫃狀態需以最新交易市場確認；StockFeel列為機能性食品同業。
  • 立弘 1780 台股上櫃公司，食品生技與天然色素／原料相關業務；StockFeel列為同業。
  • 景岳 3164 台股上櫃公司，益生菌與保健食品相關業務；StockFeel列為同業。
  • 加捷生醫 4109 台股上櫃公司，生技保健相關業務；StockFeel列為同業。
Sources（18）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.